Literature DB >> 25394324

¹H MRS characterization of neurochemical profiles in orthotopic mouse models of human brain tumors.

Keith M Hulsey1, Tomoyuki Mashimo, Abhishek Banerjee, Todd C Soesbe, Jeffrey S Spence, Vamsidhara Vemireddy, Elizabeth A Maher, Robert M Bachoo, Changho Choi.   

Abstract

Glioblastoma (GBM), the most common primary brain tumor, is resistant to currently available treatments. The development of mouse models of human GBM has provided a tool for studying mechanisms involved in tumor initiation and growth as well as a platform for preclinical investigation of new drugs. In this study we used (1) H MR spectroscopy to study the neurochemical profile of a human orthotopic tumor (HOT) mouse model of human GBM. The goal of this study was to evaluate differences in metabolite concentrations in the GBM HOT mice when compared with normal mouse brain in order to determine if MRS could reliably differentiate tumor from normal brain. A TE =19 ms PRESS sequence at 9.4 T was used for measuring metabolite levels in 12 GBM mice and 8 healthy mice. Levels for 12 metabolites and for lipids/macromolecules at 0.9 ppm and at 1.3 ppm were reliably detected in all mouse spectra. The tumors had significantly lower concentrations of total creatine, GABA, glutamate, total N-acetylaspartate, aspartate, lipids/macromolecules at 0.9 ppm, and lipids/macromolecules at 1.3 ppm than did the brains of normal mice. The concentrations of glycine and lactate, however, were significantly higher in tumors than in normal brain.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  1H MRS; 9.4 T; GBM; PRESS; human orthotopic tumor (HOT) mouse model; neurochemical profile

Mesh:

Substances:

Year:  2014        PMID: 25394324     DOI: 10.1002/nbm.3231

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  5 in total

1.  GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo.

Authors:  Tao Gong; Xia Zhang; Xinhong Wei; Shuhui Yuan; Muhammad G Saleh; Yulu Song; Richard A Edden; Guangbin Wang
Journal:  Neurochem Int       Date:  2020-10-22       Impact factor: 3.921

2.  In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.

Authors:  Vivek Tiwari; Tomoyuki Mashimo; Zhongxu An; Vamsidhara Vemireddy; Sara Piccirillo; Pegah Askari; Keith M Hulsey; Shanrong Zhang; Robin A de Graaf; Toral R Patel; Edward Pan; Bruce E Mickey; Elizabeth A Maher; Robert M Bachoo; Changho Choi
Journal:  Magn Reson Med       Date:  2020-01-30       Impact factor: 4.668

3.  Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.

Authors:  Nuria Arias-Ramos; Laura Ferrer-Font; Silvia Lope-Piedrafita; Victor Mocioiu; Margarida Julià-Sapé; Martí Pumarola; Carles Arús; Ana Paula Candiota
Journal:  Metabolites       Date:  2017-05-18

Review 4.  Brain Tumor Diagnostics and Therapeutics with Superparamagnetic Ferrite Nanoparticles.

Authors:  Fahmeed Hyder; S Manjura Hoque
Journal:  Contrast Media Mol Imaging       Date:  2017-12-11       Impact factor: 3.161

5.  Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.

Authors:  Cristina Cudalbu; Pierre Bady; Andreas F Hottinger; Monika E Hegi; Marta Lai; Lijing Xin; Olga Gusyatiner; Marie-France Hamou; Mario Lepore; Jean-Philippe Brouland; Roy T Daniel
Journal:  Acta Neuropathol Commun       Date:  2021-08-04       Impact factor: 7.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.